On the basis of encouraging preclinical activity, an anti-CEACAM5 antibody–drug conjugate with a topoisomerase 1 inhibitor payload is being tested in an ongoing phase 1 trial where recommended doses for further testing have been identified and an unconfirmed overall response rate of 15% was observed in patients with metastatic colorectal cancer.
- Scott Kopetz
- Valentina Boni
- Ildefonso Rodriguez-Rivera
